Picture EBD Group World of Partnering Opportunities 650x100px
Person › Details

Wolfgang Wienand (Lonza Group AG (SWX: LONN))

Wienand, Wolfgang (Lonza 202407c– CEO before Siegfried since 2010 before Evonik Industries)


Organisations Organisation Lonza Group AG (SWX: LONN)
  Today Lonza (Group)
  Group Lonza (Group)
  Former/major organisation Siegfried Holding AG
  Group Siegfried (Group)
Products Product contract manufacturing (biologicals)
  Product 2 contract manufacturing (drugs)

Lonza Group AG. (4/2/24). "Press Release: Wolfgang Wienand, Currently CEO of Swiss CDMO Siegfried Holding AG, Will Become Chief Executive Officer of Lonza in the Summer of 2024". Basel.

Ad hoc announcement pursuant to Art. 53 LR

> Albert M. Baehny will retire from Lonza following a transition period

The Board of Directors of Lonza today announced that Wolfgang Wienand has been appointed Chief Executive Officer (CEO), and will join the company during the summer of 2024.

Wolfgang is currently CEO of the Swiss contract development and manufacturing organization (CDMO) Siegfried Holding AG, a role he has held since 2019. Prior to this, Wolfgang first served as Chief Scientific Officer and then as Chief Strategy Officer in Siegfried’s executive leadership team. Before joining Siegfried in 2010, Wolfgang held a series of increasingly senior positions at the German specialty chemicals company Evonik Industries.

Wolfgang will succeed Albert M. Baehny, who took on the additional responsibility of CEO on an ad interim basis in October 2023 while the search for a permanent CEO took place. Albert will remain at Lonza for a transition period during the summer, before retiring from the company.

Albert M. Baehny, Chairman of the Board of Directors and CEO ad interim, Lonza, commented: “The Board is delighted to have appointed a seasoned CEO with a strong and established track record of success in the CDMO industry. Wolfgang brings a wealth of knowledge and experience to Lonza, complemented by his deep scientific and strategic expertise. With his proven leadership capabilities, Wolfgang is ideally placed to act as an ambassador for our business and lead our colleague community as Lonza enters the next chapter of its growth journey.”

Christoph Mäder, Lead Independent Director and Vice-Chairman, Lonza, added: “Wolfgang is a high-caliber leader with outstanding CDMO experience. He will be a great asset to our business. As Wolfgang takes the role of CEO, Albert Baehny will step down from his ad interim CEO position. I would like to take this chance to thank Albert for his extraordinary dedication and leadership in recent months. As Albert also plans to step down from the Board of Directors in May, I would also like to take this chance to thank him for the critical role he has played in the growth and transformation of our business during his time as Chairman.”

Wolfgang Wienand, incoming Chief Executive Officer, Lonza, commented: “I am very much looking forward to joining Lonza and leading the company into a strong future. Lonza is world class, as is the scientific, technological and market expertise of its people. It is this unique position that enables the Lonza team to push the boundaries of pharmaceutical development and manufacturing, and serve as a partner of choice for the global biopharma industry in its quest to turn breakthrough innovations into viable therapies. Together, we will enable a healthier world for patients in need.”

Note to editors:
A high-resolution image of Wolfgang is available on request from

About Lonza

Lonza is one of the world’s largest healthcare manufacturing organizations. Working across five continents, our global community of around 18,000 colleagues helps pharmaceutical, biotech and nutrition companies to bring their treatments to market. United by our vision to bring any therapy to life, we support our customers with a combination of technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work enables our customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from life-saving and life-enhancing treatments.

Our business is structured to meet our customers’ complex needs across four divisions: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients. Our company generated sales of CHF 6.7 billion with a CORE EBITDA of CHF 2.0 billion in Full-Year 2023. Find out more at

Follow @Lonza on LinkedIn
Follow @LonzaGroup on X

Lonza Contact Details

Media Inquiries:

Investor Inquiries:

Record changed: 2024-04-13


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Wolfgang Wienand

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group World of Partnering Opportunities 650x300px

» top